Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ACCELERON PHARMA INC.

(XLRN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Insider Sell: Acceleron Pharma

09/09/2021 | 05:13pm EDT


ę MT Newswires 2021
All news about ACCELERON PHARMA INC.
07:22aACCELERON PHARMA INC : Results of Operations and Financial Condition (form 8-K)
AQ
07:11aAcceleron Announces Third Quarter 2021 REBLOZYL« Net Sales
BU
10/21MERCK : Bristol-Myers To Shed Acceleron Stake Ahead Of Merck & Co.'s $11.5 Billion Acquisi..
MT
10/18ACCELERON PHARMA ALERT : Investors Should Contact Bragar Eagel & Squire, P.C. Over Tender ..
BU
10/14MERCK : Acceleron Pharma Shareholder Says Merck & Co.'s Offer Significantly Undervalues Co..
MT
10/13SHAREHOLDER ALERT : Monteverde & Associates PC Announces an Investigation of Acceleron Pha..
PR
10/13ACCELERON PHARMA : Holocene Advisors says Merck's offer undervalues Acceleron
RE
10/13ACCELERON PHARMA : Holocene Advisors says Merck's offer undervalues Acceleron
RE
10/12MERCK : Launches Tender Offer to Buy Acceleron Pharma at $180 Per Share
MT
10/07ACCELERON PHARMA : Jefferies Starts Acceleron Pharma at Hold With $180 Price Target
MT
More news
Analyst Recommendations on ACCELERON PHARMA INC.
More recommendations
Financials (USD)
Sales 2021 134 M - -
Net income 2021 -241 M - -
Net cash 2021 482 M - -
P/E ratio 2021 -43,3x
Yield 2021 -
Capitalization 10 626 M 10 626 M -
EV / Sales 2021 75,5x
EV / Sales 2022 51,3x
Nbr of Employees 312
Free-Float 87,6%
Chart ACCELERON PHARMA INC.
Duration : Period :
Acceleron Pharma Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ACCELERON PHARMA INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 11
Last Close Price 173,78 $
Average target price 177,36 $
Spread / Average Target 2,06%
EPS Revisions
Managers and Directors
Habib J. Dable President, Chief Executive Officer & Director
Kevin F. McLaughlin Chief Financial Officer, Treasurer & Senior VP
Francois Nader Non-Executive Chairman
Ravindra Kumar Chief Scientific Officer & Senior Vice President
Jay T. Backstrom Executive VP & Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
ACCELERON PHARMA INC.35.83%10 626
GILEAD SCIENCES, INC.16.25%84 921
BIONTECH SE258.67%70 618
WUXI APPTEC CO., LTD.23.63%64 231
REGENERON PHARMACEUTICALS22.57%61 565
VERTEX PHARMACEUTICALS-22.12%47 753